Carey Williams
Family · Deatsville, ALNPI 1225227093
Payments from drug & device makers
Across 151 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$551
- AstraZeneca$339
- Astellas Pharma US Inc$246
- Novo Nordisk$220
- Amgen$196
- GSK$149
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,59891%
- Education$2469%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $551 |
| AstraZeneca | 17 | $339 |
| Astellas Pharma US Inc | 4 | $246 |
| Novo Nordisk | 13 | $220 |
| Amgen | 9 | $196 |
| GSK | 9 | $149 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $121 |
| Exact Sciences | 6 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| Neurocrine Biosciences, Inc. | 3 | $69 |
| Bayer | 3 | $62 |
| Vision Quest Industries Inc. | 1 | $56 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Inogen, Inc. | 2 | $46 |
| Intuitive Surgical | 1 | $45 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Dexcom, Inc. | 2 | $39 |
| Mylan Specialty L.p. | 2 | $34 |
| UCB, Inc. | 1 | $29 |
| Boehringer Ingelheim | 2 | $27 |
| Pfizer | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Medtronic | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Merck | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,844 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $120,909 |
| MounjaroTirzepatide | 73 | $111,182 |
| JardianceEmpagliflozin | 99 | $100,408 |
| OzempicSemaglutide | 63 | $89,509 |
| EliquisApixaban | 80 | $65,097 |
| TrulicityDulaglutide | 26 | $44,545 |
| JanuviaSitagliptin Phosphate | 45 | $41,764 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 39 | $41,641 |
| VascepaIcosapent Ethyl | 45 | $31,975 |
| FarxigaDapagliflozin Propanediol | 29 | $31,853 |
| RybelsusSemaglutide | 22 | $31,560 |
| SynjardyEmpagliflozin/Metformin Hcl | 32 | $28,378 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $25,336 |
| Aprepitant | 11 | $24,456 |
| LinzessLinaclotide | 25 | $22,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Spiriva Respimat, Combivent Respimat | $27 | $169,779182 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy, Novolog | $220 | $140,710114 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $149 | $131,101124 claims |
| PfizerEliquis | $25 | $65,09780 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $339 | $49,64447 claims |
| MerckJanuvia | $14 | $41,76445 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $22 | $41,64139 claims |
| AbbVieLinzess, Qulipta | $551 | $35,36437 claims |
| Johnson & JohnsonXarelto | $20 | $19,83824 claims |
| Astellas Pharma US IncMyrbetriq | $246 | $13,16814 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $121 | $11,36217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.
Other family in Deatsville
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.